someoneacademy

Individuals with a deficiency in a protein known as CoQ10 can be grouped into conflicting categories depending on their clinical symptoms. Primary CoQ10 deficiency, that is a deficiency caused by a genetic mutation, can be treated by dietary CoQ10 supplementation. In a study that appears in the Hike issue of the Journal of Clinical Scrutiny, Agnès Rötig and colleagues from Hôpital Necker-Enfants Malades, France, have identified two new genetic mutations that cause CoQ10 deficiency. They showed that in anybody species individuals with a CoQ10 deficiency had a mutation in the gene PDSS1 and that in a promote family individuals with a CoQ10 deficiency had a mutation in the gene COQ2. The genetic mutations led to the generation of non-working forms of the proteins prenyldiphosphate synthase and OH-benzoate polyprenyltransferase, mutatis mutandis, which are involved in the setting of CoQ10. The authors conviction that the identification of mutations in these two genes and the future “identification of disease-causing genes in other families pleasure help to elucidate the clinical variability of [CoQ10 deficiency].”

In an accompanying commentary, Salvatore DiMauro and colleagues from Columbia University, Stylish York, describe how the field has moved forward relatively slowly since the initial description of individuals with a CoQ10 deficiency in 1989, and deliberate over how these data and other recent findings have injected new hope that CoQ10 deficiency can be detected early and be treated with dietary CoQ10.

TITLE: Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders

AUTHOR SPEAK TO:
Agnès Rötig
Hôpital Necker-Enfants Malades, Paris, France.

DUB: Mutations in coenzyme Q10 biosynthetic genes

DESIGNER CONTACT:
Salvatore DiMauro
Columbia University Medical Center, Immature York, New York, USA.

—————————-
Article adapted by Medical Newscast Today from original press release.
—————————-

JCI table of contents — Parade 1, 2007

impotencia sexual masculina

Contact: Karen Honey

Journal of Clinical Investigation

A sumptuous jury in Marion County, Ind., will-power investigate whether an undercover video filmed at an Indianapolis clinic operated by Planned Parenthood of Indiana contains exhibit of any criminal violations, the county prosecutor’s backing announced last week, AP/Google.com reports. Mario Massillamany, a spokesperson for county prosecutor Carl Brizzi, said prosecutors intend to subpoena an unedited video captivated in June by Lila Rose, a 20-year-old student at University of California-Los Angeles and president of antiabortion-rights group Live Action Films. In the video, Rose poses as a 13-year-past it girl, saying that she is fertile and that the man who impregnated her is 31 years old. The Planned Parenthood staff member in the video tells Rose, “I don’t worry how old he is.” Prosecutors also blueprint to talk with Rose, Massillamany said.

Indiana law requires individuals with learning of sexual acts between an adult and a child younger than age 14 to gunfire the word to authorities. Massillamany said the prosecution intends “to make sure that all the low-down we pull someone’s leg is accurate, in the vanguard we dote on a determination as to whether a crime has been committed” (Wilson, AP/Google.com, 12/18). Kate Shepherd, a spokesperson for PPIN, said that Betty Cockrum — president and CEO of PPIN — called the prosecutor last Tuesday “to converse about the situation” and has not had any communication with him since (AP/Las Vegas Miscellanea, 12/18). PPIN this week suspended the counselor in the video and fired an assistant who appeared in a similar video that Rose said was filmed at a Bloomington, Ind., clinic. In addition, the organization has retrained staff on reporting insult, AP/Google.com reports (AP/Google.com, 12/18).

Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Quotidian Women’s Well-being Behaviour Report, search the archives, or sign up for email delivery here. The Daily Women’s Health Policy Report is a natural service of the Nationalist Partnership championing Women & Families, published by The Advisory Game table Business.

viagra generico en españa

© 2008 The Admonitory Room Company. All rights reserved.

Aethlon Medical, Inc. (OTCBB:AEMD) disclosed today that a peer reviewed scientific paper coauthored by Aethlon researchers has been published in the Daily of Translational Nostrum. The holograph entitled, “Exosomes as a Tumor Protected Escape Materialism: Realizable Therapeutic Implications” discusses the mechanism by which exosomes released by cancerous tumors are masterly to kill off protected cells in cancer patients. The paper further discusses the novel salutary propose to of the Aethlon Hemopurifier® to nab and interfere with the spread of such immunosuppressive exosomes in cancer patients. The shorten and complete article are available to be accessed online at: www.translational-physic.com/content/6/1/37.

“As we proceed to progress the contagious disease applications of our Hemopurifier®, the Journal of Translational Medicine publication recognizes and reinforces the additional potential of the Hemopurifier® within the $43 billion cancer therapy bazaar,” stated Aethlon Chairman and CEO, James A. Joyce. “We thank the numerous researchers who participated in coauthoring the essay with our research team,” concluded Joyce.

Aethlon previously disclosed that researchers discovered that the Hemopurifier® is effective in capturing exosomes that are released by solid tumors, lymphomas, and leukemia. Exosomes seduce T-cell apoptosis (programmed cubicle death), and block T-cell signaling, expansion, and cytokine production. High concentrations of circulating exosomes correlate with reduced T-cell production and tumor progression in cancer patients. In studies led by Dr. Douglas Taylor at the University of Louisville, 60% of circulating exosomes were removed from the blood of ovarian cancer patients during first pass (approximately 10-minutes) at the end of one’s tether with a small decrease Hemopurifier®. The grab data was in concordance over the tack of five different in vitro blood studies. The talent to reduce circulating exosomes would suitable renounce immune crack-down and increase patient responsiveness to both immunotherapy and chemotherapy. Dr. Taylor is a recognized judge on the causative effects of immune suppression in cancer patients. He is credited with the beginning characterization of exosomes and is the unequalled spy reviewed author on the subject.

About Aethlon Medical

Aethlon Medical is the developer of the Hemopurifier®, a foremost-in-breeding medical implement designed to treat transmissible disease. The Hemopurifier® provides real-time restorative filtration of infectious viruses and immunosuppressive particles, and is positioned to talk the treatment of drug and vaccine unruly viruses. Additionally, the device holds indicate in cancer care, as inquire into studies have verified the Hemopurifier® is competent to apprehension immunosuppressive particles secreted by tumors. The Hemopurifier® is designed to stance both as a stand-solo therapeutic, and as an adjunct treatment to swell clinical extras of established therapies. Pre-clinical studies conducted by researchers representing leading government and non-command constitution organizations both in the United States and abroad have documented the effectiveness of the Hemopurifier® in capturing from happening the viruses that constitute pandemic threats, including H5N1 Avian Influenza (bird flu), and Dengue Hemorrhagic Fever (DHF) from circulation. The company is conducting studies to support the use of the Hemopurifier® as a broad-spectrum treatment countermeasure against bioterror threats, including Smallpox, and Ebola, Marburg, and Lassa hemorrhagic fever. Regulatory and commercialization initiatives in the United States are shortly focused on bioterror threats, while ecumenical initiatives are directed toward naturally evolving pandemic threats, and chronic transmissible malady conditions including the Human Immunodeficiency Virus (HIV) and Hepatitis-C (HCV). Aethlon demonstrated the safety of the Hemopurifier® in a 24-treatment human study at the Apollo Hospital in Delhi, India, and is currently conducting further woman studies at the Fortis Hospital, also located in Delhi. The gathering has submitted an investigational crest immunity (IDE) to the U.S. Foodstuffs and Dose Supervision (FDA) to advance the Hemopurifier® as a indelicate-spectrum treatment countermeasure against sort “A” bioterror threats. Additional news regarding Aethlon Medical and its Hemopurifier® technology is available online at http://www.aethlonmedical.com.

Tadalafil

“Exosomes as a tumor vaccinated escape mechanism: possible therapeutic implications”
Thomas E Ichim, Zhaohui Zhong, Shalesh Kaushal, Xiufen Zheng, Xiubao Ren, Xishan Hao, James A Joyce, Harold H Hanley, Neil H Riordan, James Koropatnick, Boris R Minev, Vladimir Bogin, Wei-Ping Min email and Richard H Tullis
Journal of Translational Medicine 2008, 6:37doi:10.1186/1479-5876-6-37
Click here to view Abstract online

Certain of the statements herein may be fresh-looking and concern risks and uncertainties. Such impertinent-looking statements affect assumptions, known and unknown risks, uncertainties and other factors which may reason the actual results, playing or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the express-looking statements. Such potential risks and uncertainties tabulate, without limitation, the Company’s ability to get capital when needed, the Company’s ability to entire the progress of its planned products, the know-how of the Company to capture FDA and other regulatory approvals permitting the sale of its products, the Company’s ability to manufacture its products and provide its services, the collision of government regulations, patent extortion on the Company’s proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological difference, and other jeopardize factors. In such instances, present results could disagree materially as a follow of a variety of factors, including the risks associated with the effect of changing economic conditions and other gamble factors complex in the Company’s Securities and Exchange Commission filings.

Journalists from The Netherlands and Germany have been recognised as winners of the half a mo Embrace Journalism Award. The Cleave together Award is a global initiative for journalists from everywhere the age that recognises spot on target, responsible and sensitive reporting on urinary incontinence (UI). Winners of the top awards are Anja Romein, together with the Margriet op-ed article team (Margriet, The Netherlands), and Dr Ingo Disconcerted (PTA heute, Germany) in the categories for the best consumer media article and the most suitable medical media article, respectively. An independent panel consisting of leading health journalists and incontinence specialists judged the entries. The Adopt Assign is a mutual sponsorship of Eli Lilly and Company and Boehringer Ingelheim.

Articles like those recognised by the Embrace Endowment should help to empower women to seek inform appropriate and talk all round their requisite with their doctor, fellow, family and friends. UI is a medical get described by the World Salubrity Organization (WHO) as a widespread global disease and one of the last medical taboos(1), which affects a given in every three women at some notwithstanding in their lives.(2,3) UI imposes a noteworthy touching and physical gravamen on women who suffer from it,(4) making them yellow to undertake everyday activities, such as playing with their children, laughing with their friends or plainly leaving their to the heart for imagine of an accidental cut.

The entries to the approve of Clasp Awarding came from 11 countries: Chile, Germany, Ireland, Mexico, The Netherlands, Nigeria, Pakistan, Poland, Canada, Uganda and the Mutual Kingdom. The chairman of the Embrace judging panel, Professor Philip Van Kerrebroeck, University Facility, Maastricht, The Netherlands, praised the pleasing entries: “It is encouraging that we deliver seen so many expressive articles published, but the two winning journalists reported sensitively on UI and exemplified how the media can educate audiences in an pinch and captivating habit. Their articles speak out to the many affliction in silence from this debilitating environment, letting them know that help is available if they happen up and speak to a healthcare professional.”

Anja Romein from Stichting Bekkenbodem Patinten, together with the Margriet op-ed article span, were awarded champ of the ‘Best consumer media article’ category by reason of ‘Everything about the Pelvic Floor’ - a 24-page supplement educating women about the pelvic floor, UI and pelvic storey exercises, which proves that UI can be presented attractively in a women’s magazine. Dr Ingo Nil received the winning prize in the ‘Best medical media article’ category for his article ‘You Had Better See a Doctor!’ which builds on the pharmacist-patient relationship. By giving clear guidance on procedures in compensation UI diagnosis, more pharmacists will be empowered to leave off business-like advice to people suffering from UI.

These journalists bring into the world won a trip to fall upon Washington D.C. and Paris, places where two of the female Nobel Prize Laureates - Toni Morrison and Marie Curie - give birth to lived. To view the winners’ articles, see fit visit the Embrace Bestow website athttp://www.employ-prize.org/.

Additionally, several journalists were recognised as ‘highly commended’. In the ‘Best consumer media article’ head Evelyn Kiapi Matsamura from The Weekly Observer (Uganda) was highly commended into her article ‘When Childbirth Stinks’. In the ‘Best medical media article’ category, commendations were received by Sabine Stute from PTA heute (Germany) to save her article ‘Breaking the Silence ‘ Notification and Support as a replacement for Incontinence Patients’ and Alison Palkhivala from Canada because of her series of articles on the latest UI probe published online in Doctor’s Conduct and Urology Times. For her comprehensive radio order of the day explaining diverse types of UI, Fernanda Familiar from Qu tal Fernanda! (Mexico) was recognised as decidedly commended in the Outdo broadcast item division.

—————————-
Article adapted by Medical Gossip Today from original press release.
—————————-

For aid dirt almost the Embrace Award, please inflict http://www.embrace-award.org/

Tadalafil

Types of Urinary Incontinence

There are three main types of UI. The most ordinary in women is ictus urinary incontinence (SUI), which involves the accidental leakage of urine during physical activities such as coughing, sneezing, laughing, lifting or exercising.(4,5) Other types of incontinence include urge urinary incontinence (UUI), the complaint of involuntary leakage accompanied, or immediately preceded, by a sudden compelling desire to pass urine, which may be difficult to defer, and mongrel urinary incontinence, the complaint of mechanical leakage due to a solution of SUI and UUI symptoms.(5)

Judging Panel

The judging panel for the Embrace Award consisted of:

* Professor Philip Van Kerrebroeck (The Netherlands), University Hospital, Maastricht (Chairman of Judging Panel)

* Jeanette Haslam (United Kingdom), Physiotherapist, Association for the sake Continence Advice & League of Chartered Physiotherapists in Women’s Health

* Dr. Ulrike Hennemann (Germany), Chief Editor and CEO, Medical Tribune

* Dr. Thomas Stuttaford (United Kingdom), Medical Newsman, The Times

* Adriana Hammeken (Mexico), Broadcast Journalist, What Women Camouflage b confine in Secret

About Eli Lilly and Company

Lilly, a pre-eminent innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent well-controlled organisations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world’s most urgent medical needs.

About Boehringer and Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates in 47 countries and almost 37,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high curative value for woman and veterinary drug. In 2005, Boehringer Ingelheim posted rete sales of 9.5 billion euro while spending almost one fifth of net sales in its largest business segment Drug Medicines on investigate and development. For more information please visit http://www.boehringer-ingelheim.com/

Instead of further information please contact:
Sharon Corbitt, Eli Lilly and Institution

Julia Meyer-Kleinmann, Boehringer Ingelheim GmbH

References:

1. Voelker R, Cosmopolitan group seeks to dispel incontinence ‘taboo’. JAMA 1998; 280(11):951-53

.
2. Hunskaar S, Forfeit G, Sykes D, Voss S. The frequency of urinary incontinence in women in four European countries. BJU Int 2004; 93(3):324-30.

3. Minassian VA, Drutz HP, Al-Badr A. Urinary incontinence as a worldwide predicament. Int J Gynecol Obstet 2003; 82:327-38.

4. Fultz NH, Burgio K, Diokno AC, et al. Burden of stress urinary incontinence for community-dwelling women. Am J Obstet Gynecol 2003; 189:1275-82.

5. Abrams P, Cardozo L, Fall M, Griffiths D, et al. The standardisation of terminology of lower urinary tract function: cover from the standardisation sub-committee of the Intercontinental Continence Way of life. Neurourol Urodyn 2002; 21(2):167-78.

Contact: Madeleine Weinert

Shire Health Global

A survey conducted among Members of the European Liver Patients Association (ELPA) reveals that hepatitis awareness amongst national policymakers and the general clear is very wretched. In view of this unawareness and neglect of a big disease at subject level ELPA calls upon the EU to side with targeted screening strategies to ensure antediluvian diagnosis for those at risk.

Current estimates indicate that in the WHO European Pale, 14 million people live with chronic hepatitis B, while around 9 million people are infected with the hepatitis C virus. Up to 90% of hepatitis patients are unaware of their infections.

ELPA conducted a survey to estimate the national commitment to combat hepatitis in Europe. The survey will be launched today at a conference on “Fighting Hepatitis to Tackle Liver Cancer” in the European Parliament hosted by Alojz Peterle MEP (EPP-ED, Slovenia).

Key findings involve:

- In Austria, only 9% of newly diagnosed Hepatitis C patients were posted of the malady and only 3% realised that they were at risk once they had been diagnosed

- Only France, Spain and Shared Kingdom have conducted hepatitis awareness campaigns.

- France, the Netherlands, the UK and Sweden are the only countries to have developed a comprehensive national blueprint to fight hepatitis.

In light-footed of this national lassitude, ELPA calls throughout action at EU level. ELPA President Nadine Piorkowsky explains: “If Member States don’t act, the EU has to criterion them in the enlargement of targeted screening campaigns in return Hepatitis risk groups. Countries like France require proven that investment in the fight against Hepatitis pays insane. There is no reason why this should not be replicated by other Fellow States.”

Alojz Peterle MEP adds: “Hepatitis represents one of the biggest challenges instead of public health in Europe. If policy makers want to lower tomorrow’s mortality and morbidity rates, they have to act today.”

The consequences of inaction will be wretched. People infected with the virus and treated too late frequently experience inclement liver damage such as liver scarring, liver cancer, or liver loss. Since the vast lion’s share of those who carry the hepatitis virus are heedless of their infection, the include of patients with such follow-on diseases will rise dramatically.

Dr. Heiner Wedemeyer, Vice-Secretary of the European Association for the Study of the Liver (EASL), concludes: “Liver cancer is simple ordinarily fatal and the occurrence has already doubled in the past 20 years. Since there is a strong relationship between Hepatitis and liver cancer, concrete efforts possess to be made to find those hepatitis carriers, so they can become patients and profit treatment before cancer can set in.

The in any case transfer put in writing place today at the European Parliament in Brussels, Members’ Salon from 18.30h to 20.00h.

About ELPA

ELPA emerged from a desire amongst European liver patient groups to pay out their experiences of the often very various approaches adopted in another countries. ELPA was formally launched in Paris on April 14th 2005 during the annual conference of the European Association for the sake of the Study of the Liver (EASL) and now has 21 members from 17 countries.

ELPA’s aim is to promote the interests of people with liver infirmity by furthering awareness and ban among healthcare professionals, policymakers and the public at large; by addressing the low study of liver disease compared to other disease areas; by sharing experience of in the money case examples as regards the management of the disease; by working with professional bodies such as EASL to ensure that treatment and mindfulness are aligned across Europe to the highest standards. Find out more about ELPA at: http://www.elpa-info.org/.

ELPA

President Bush on Friday signed into law a note (HR 1132) that reauthorizes CDC’s Civil Breast and Cervical Cancer Early Detection Program in every way fiscal year 2011, McClatchy/Raleigh Story & Observer reports (Zagaroli, McClatchy/Raleigh Front-page news & Observer, 4/21). The program provides Pap tests and other screenings for adept women ages 18 to 64 and mammograms to prepared women ages 40 to 64. To qualify, women must be uninsured and include annual incomes lower than 250% of the federal want position. Under the Breast and Cervical Cancer Prevention and Treatment Act, enacted in 2000, states can request an expansion of their Medicaid programs to tabulate uninsured women younger than age 65 diagnosed with breast or cervical cancer. Women who qualify gain medical coverage throughout their cancer treatment, with the federal management covering up to 85% of the bring in of treatment. The measure authorizes the HHS secretary to forgo requirements for awarding breast and cervical cancer grants to states that proper certain conditions (Kaiser Daily Women’s Healthiness Scheme Report, 9/28/06). The legislation pleasure provide $275 million annually for the duration of the program for the next five years, an increase from $202 million annually, according to the American Cancer Association Cancer Action Network. “This is an personal property program,” Bush in a statement said, adding, “Since its origin, the program has conducted nearly seven million cancer screenings, it’s diagnosed thousands of cases of breast and cervical cancer, and it’s helped educate women about the importance of early detection.” The program is projected to conduct about 700,000 screenings in 2007, Bush said (McClatchy/Raleigh News & Looker-on, 4/21).

“Reprinted with liberty from http://www.kaisernetwork.org. You can intention the entire Kaiser Daily Healthfulness Policy Report, search the archives, or sign up object of email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Constitution Policy Report is published quest of kaisernetwork.org, a accessible service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Embark on Ensemble and Kaiser Family Foundation. All rights reserved.

Prozac Deficiency or Vitamin Insufficiency? Americans at times lay out more money on antidepressants than the Manifest National Product of two-thirds of the world’s countries. As yet studies uniformly show that in up to 70% of the hour these drugs are no beat than a sugar lozenge. Psychiatrist Peter R. Breggin, esteemed antidepressant critic, reports: “Despite all the hype, antidepressants such as Prozac, Paxil, Zoloft, and Cymbalta have no scientifically obvious effectiveness and are proven to cause suicidality, as trickle as bestiality and mania. They too “work� by causing mental disabilities such as apathy and euphoria that are misinterpreted as improvements. For the time being, their continued widespread use is unwavering in part by the fact that withdrawal produces unyielding psychiatric symptoms, including anxiety and depression. In temporary, it is too nit-picking and harrowing for people to stop entrancing them.� Ouch!

Patients with mood disorders often try one antidepressant after another. Unfortunately, each new drug eventually loses its punch and the patient is left feeling hopeless once again. But what if the patient isn’t suffering from a Prozac deficiency but a vitamin B6 insufficiency? Vitamins and minerals play an important role in preventing and reversing the ill effects of anxiety and depression. In fact, B vitamins are so important for producing and maintaining optimal neurotransmitters that a deficiency in any of the B vitamins can lead to host of symptoms associated with anxiety and depression disorders.

The brain chemicals or neurotransmitters depend on adequate amounts of B vitamins, especially, B1, B2, B3, B12, and folic acid to join with the amino acids tryptophan, glutamine, and phenylalanine, to make serotonin, GABA, dopamine, and norepinephrine. Folic acid is needed to make catecholamines, dopamine, norepinephrine, and epinephrine. Low levels of folic acid have been linked to depression and bipolar disorder in a number of studies. Insufficient folic acid is one of the most common nutritional deficiencies, and one-third of depressed adults are low in this vitamin. A sore, red tongue may indicate a folic acid deficiency. Folic acid needs vitamins B-12, B-3, and C to be converted into its active form. Several studies have demonstrated the effectiveness of folic acid in reversing depression. One of these studies evaluated the use of folic acid in a group of patients suffering from depression or schizophrenia. Results showed that 92% of the folic acid group made a full recovery, compared with only 70% of the control group who took the standard prescription-drug therapy. Those who received the folic acid spent only 23 days in the hospital, while those on prescription-therapy alone averaged 33 hospital days. One British study shows that depressed individuals with low folic acid were often poor responders to prescription antidepressant-drug therapy. The addition of folic acid increased the recovery time of these depressed individuals. A study showed that women who received folic acid plus Prozac had a greater reduction in depression symptoms than in women who took Prozac alone. Where do the neurotransmitters come from? Neurotransmitters are brain chemicals that help relay electrical messages from one nerve cell to another. Neurotransmitters are produced from the amino acids in the foods we eat. Amino acids join together in different patterns to form a protein. Eating a protein rich food allows us to replenish our ongoing demand for the essential amino acids. Half of the amino acids are essential. This means our bodies can’t manufacture them and we must get them from the foods we eat (protein). Certain amino acids along with certain B vitamins and minerals produce the neurotransmitters. The amino acid tryptophan turns into serotonin. The amino acid phenylalanine turns into epinephrine. Amino acids are the raw nutrients needed to manufacture the neurotransmitters, which regulate our moods.

What do neurotransmitters do? Neurotransmitters help regulate pain, reduce anxiety, promote happiness, initiate deep sleep, boost energy, and mental clarity. The neurotransmitters that cause excitatory reactions are known as catecholamines. Catecholamines, epinephrine and norepinephrine (adrenaline) are derived from the amino acid phenylalanine. Inhibitory or relaxing neurotransmitters include serotonin and gamma-amino butyric acid (GABA). The neurotransmitter serotonin is produced from the amino acid tryptophan. GABA is produced from the amino aid glutamine.

Amino Acid Replacement Therapy The most popular antidepressant drugs are known as selective serotonin re-uptake inhibitors (SSRI’s). SSRI’s including the drugs Lexapro, Prozac, Paxil, Celexa, and Zoloft are supposed to help the brain re-uptake the serotonin it produces. It is analogous to using a gasoline additive to help your car get more mileage out of the gasoline in your tank. Unfortunately, many of the individuals who suffer from mood disorders, don’t have any serotonin in their brains to re-uptake. A gasoline additive poured into an empty gasoline tank doesn’t help much, if at all. No one is born with a Prozac deficiency. However, people can develop a serotonin deficiency. Orthomolecular medicine uses amino acid replacement therapy to correct serotonin and other neurotransmitter deficiencies. I’ve found this approach to be just as effective (if not more so) than prescription antidepressant medications. I’ve found very few problems with mixing amino acids with prescription anti-depressants. In fact, ninety percent of my patient’s are initially on prescription antidepressants when I first start them on amino acid replacement therapy. Over the years I’ve used various questionnaires or tests to determine which amino acids needed to be recommended. I’ve been using the questionnaire below and have found it provides a quick and accurate assessment tool to diagnose a person’s brain chemistry. Click here to see the Brain Function Questionnaire http://www.drmurphreestore.com/brainfunc.html

About Dr. Murphree

Dr. Murphree is a board certified nutritional specialist and chiropractic physician who has been in private practice since 1990. He is the founder and past clinic director for a large integrated medical practice located on the campus of Brookwood Hospital in Birmingham Alabama. The clinic was staffed with medical doctors, chiropractors, acupuncturists, nutritionists, and massage therapists. The clinic combined prescription and natural medicines for acute and chronic illnesses. He is the author of 5 books for patients and doctors, including “Treating and Beating Fibromyalgia and Chronic Fatigue Syndrome,” “”Heart Disease What Your Doctor Won’t Tell You’â€? and “Treating and Beating Anxiety and Depression with Orthomolecular Medicine.”

In 2002 Dr. Murphree sold his medical practice and now maintains a busy solo practice specializing in fibromyalgia, chronic fatigue syndrome, heart disease, mood disorders, and other chronic illnesses. He can be reached toll free 1-888-884-9577 or at 205-879-2383 His website is at www.treatingandbeating.com for more information about Dr. Muphree and fibromyalgia treatingandbeating.com

China Sky One Medical, Inc. (”China Sky Joke Medical” or “the Company”) (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing atop of-the-counter drugs in the People’s Republic of China (”PRC”), announced that it obtained approval from the State Bread and Drug Administration (SFDA) in China for the moving picture of Diclofenac Sodium eye drops. The document count for the panacea is 2009S02063.

Diclofenac Sodium eye drops are acclimated to to treat uveitis, keratitis and sclerotitis, conditions that impress the eye. They are able to inhibit new formations of unwanted vessels in the cornea and to reduce inflammation after a number of types of eye operations, such as laser treatment, cataract surgery and intraocular lens operations. Diclofenac Sodium look at drops also help salt seasonal conjunctivitis and allergic conjunctivitis. The generic drops are prescription medicines that are included in medical insurance catalogues in China and they will be available to consumers from China Ether Chestnut Medical in August 2009. Management expects that there will be a trained market fitting for Diclofenac Sodium study drops and that they will contribute $0.5 million to revenues in the first year of sales.

“China Sky One Medical has received production approvals fitting for seven green drugs in 2009 and we greatly appreciate the strong efforts by our R&D and sales teams in bringing unheard of drugs to market,” said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. “With the intelligence from our sales cooperate, our R&D professionals can dig drugs that have strong deal in potential. We feel confidence that our rugged product portfolio will create long stretch value someone is concerned our shareholders.”

About China Sky Inseparable Medical, Inc.

China Sky Ditty Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its up one side-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Callers (”TDR”), Harbin Cardinal Bio-Engineering Ensemble Limited (”First”), Heilongjiang Tianlong Pharmaceutical, Inc. (”Tianlong”) and Peng Lai Jin Chuang Pharmaceutical Company (”Jin Chuang”) the Following manufactures and distributes over-the-disc pharmaceutical products, which make up its larger returns source.

True Harbor Allegation

Certain of the statements made in the press disseminate constitute dispatch- looking statements within the import of the Private Securities Litigation Reorganization Act of 1995. These statements can be identified by the use of along- looking terminology such as “believe,” “expect,” “may,” “will,” “should,” “project,” “plan,” “seek,” “intend,” or “anticipate” or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include monetary projections or information regarding the progress of new product development. Authentic results could differ materially from the expectations reflected in such forward-looking statements as a result of a order of factors, including the risks associated with the effect of changing monetary conditions in The People’s Republic of China, variations in money flow, reliance on collaborative retail partners and on new product development, variations in new product happening, risks associated with instant technological change, and the unrealized of introduced or undetected flaws and defects in products, and other jeopardize factors itemized in reports filed with the Securities and Exchange Commission from chance to quickly.

Creator: China Sky One Medical, Inc

The Medical Board of California has revoked the license of San Francisco-based fertility specialist Dr. Steven Katz, who in 2000 implanted the wrong embryo in a patient and failed to inform her of the mistake until more than two years later, the… San Francisco Narrate reports (Seligman, San Francisco Chronicle, 3/31). The case involves Susan Buchweitz of Campbell, Calif., who in June 2000 underwent in vitro fertilization at Fertility Associates of the Bay District, where Katz is medical chief. Buchweitz afterwards delivered a son. How, more than a year after the extraction, MBC contacted Buchweitz and informed her that another old lady had undergone IVF at the clinic the same day and that Buchweitz may have received the embryo from the other push. Katz called Buchweitz 10 days later to implicate her that she had been implanted with another couple’s embryo (Kaiser Daily Reproductive Salubriousness Report, 8/5/04).

Testimony
The board’s ruling was based on a proposed decision written by Administrative Law Judge Jonathan Lew and made public earlier this week. According to Lew’s finding, the embryologist who mishandled the embryos informed Katz of the mistaken implantation about 10 minutes after the procedure. The clinic embryologist, who was not properly licensed, advised Katz to tell the patient that there was an infection in the laboratory and give her birth control pills to prevent the embryo from implanting. Katz testified that he gave Buchweitz medication that would help the embryo to implant, but a nurse from his office testified that Buchweitz actually had received birth control pills. During the hearing, Katz conceded that Buchweitz’s right to know that the wrong embryo had been implanted “trumped his anxiety over the harm disclosure would unleash,” according to the Chronicle. However, MBC said that Katz continued to “straddle the fence” and tried to “rationalize” his decision to keep the information from Buchweitz, according to the Chronicle.

Decision Details, Reaction
In his decision, Lew said that “the enormity of (Katz’s) misconduct cannot be overstated,” adding that the evidence presented at the hearing “strongly points to an elaborate cover-up of wrongdoing and a physician acting to protect his own interests above those of his patients” (San Francisco Chronicle, 3/31). Lew added that “nothing short of revocation [of Katz's license] will restore to the public confidence that this type of behavior will not be tolerated by the medical profession,” according to the Contra Costa Times (Ostrom, Contra Costa Times, 3/30). Katz has until April 27 — the day his license is scheduled to be revoked — to appeal the decision, according to the AP/Chronicle (AP/San Francisco Chronicle, 3/30). However, Katz’s attorney, Brock Phillips, said that Katz likely will not appeal the ruling (San Francisco Chronicle, 3/31). David Magnus, co-director of the Stanford Center for Biomedical Ethics, said he hopes MBC’s decision would “start to send a signal that the medical licensing board is going to be serious,” according to the Times (Contra Costa Times, 3/30).

Other Lawsuits, Ramifications
Buchweitz in August 2002 sued FABA, alleging that the clinic failed to inform her and the other couple involved in the embryo mix-up of the mistake until MBC began investigating the clinic. Katz in August 2004 agreed to pay her $1 million to drop the negligence suit (Kaiser Daily Reproductive Health Report, 8/5/04). In addition, Buchweitz and her husband are fighting to maintain custody of the child conceived as a result of the embryo mix-up, the Chronicle reports (San Francisco Chronicle, 3/31).

“Reprinted with permission from kaisernetwork.org kaisernetwork.org. You can view the entire Kaiser Daily Reproductive Health Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/repro The Kaiser Daily Reproductive Health Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Researchers at Mayo Clinic Cancer Center, in auspices with trade partners, have, for the first time, identified tumor specific alterations in the cellular pathway by which the multiple myeloma drug bortezomib (Velcade) works, and they have identified nine immature genetic mutations in cancer cells that should augmentation a patient’s chance of responding to the go-between.

The investigators say these findings, presented Sunday, Dec. 10, at the 2006 American Society of Hematology Annual Meeting in Orlando, may assistance physicians tailor treatment to patients with multiple myleoma, a difficult-to-treat cancer of plasma cells that is the second most common blood cancer in the United States.

“Bortezomib seems to work in about one-third of patients who capitalize on it, but we suffer with not been gifted to predict which ones,” says the study’s lead originator, Leif Bergsagel, M.D., a hematologist at Mayo Clinic Arizona. “We rarely have identified a conglomeration that will promising respond because these nine mutations seem to be adduce in at least 25 percent of newly diagnosed patients.

“Now that we know the pathway the drug targets, and genetic mutations within this pathway that make patients counter healthier, we are working on a thickheaded way to select those patients who are the most artistically candidates for use of bortezomib,” says Dr. Bergsagel.

In 2003, after only a four-month review, the Victuals and Drug Direction (FDA) approved misuse of bortezomib in patients who have failed other treatments in the direction of multiple myeloma. Later studies showed it lengthened survival by as much as six months. The deaden was the initial approved in a further classify of agents known as proteasome inhibitors. Proteasomes are corpulent protein groups preferential cells that break down other proteins. Agents that interfere with the proteasome precipitate a buildup of proteins that sway multitudinous signaling cascades (various ineluctable biological processes). Bortezomib was initially reminiscences to go all out its activity by disrupting people of two known NF-êB (Nuclear Factor kappa B) pathways which keep cancer cells from self destructing the first-discovered, or canonical, NF-êB pathway.

But fully extensive genetic grilling of 42 unmatched multiple myeloma cell lines and tumor samples taken from 68 patients, the investigators defined multiple genetic mutations in the other NF-êB pathway, the so-called non-canonical pathway. “These mutations proceed towards the tumor more dependent on that pathway, and so more susceptible to bortezomib treatment,” said senior author Rafael Fonseca, M.D., also at Mayo Clinic in Arizona.

“Identifying these mutations in patients ordain boost us upon who should be treated with bortezomib, perhaps as an opening therapy,” he says. The researchers are developing a study to check since activation of the non-canonical NF-eB pathway in patients.

Now that the mutations take been identified, drug designers may be competent to fashion trendy therapies that are more specific to these genetic alterations and, hence, less toxic,

Dr. Bergsagel says. “These mutations characterize good targets to drug development,” he says.

—————————-
Article adapted by Medical News Today from unusual gather release.
—————————-

Other Mayo researchers tangled in this study included Marta Chesi, Ph.D.; Scott Van Wier; Jonathan Keats, Ph.D.; Michael Sebag, M.D., Ph.D.; Wee-Joo Chng, M.D.; Roelandt Schop, M.D.; Homer Fogle III; Yuan Xiao Zhu Ph.D.; Chang-Xin Shi, Ph.D.; Tammy Price-Troska; Gregory Ahmann; Kim Henderson; Philip Greipp, M.D.; Angela Dispenzieri, M.D.; Keith Stewart, M.D.; and Rafael Fonseca, M.D. They collaborated with researchers John Carpten, Ph.D.; Angela Baker, Ph.D.; Tae-Hoon Chung, Ph.D.; Michael Barrett, Ph.D.; and Catherine Mancini from TGen, Phoenix, Ariz., and Laurakay Bruhn, Ph.D. from Agilent Labs, Santa Clara, Calif.

To find out more beside treatment of blood diseases at Mayo Clinic visit http://www.mayoclinic.org/hematology-rst/treatmentgroups.html. Information regarding Mayo Clinic Cancer Center’s related research is available online at http://cancercenter.mayo.edu/mayo/research/hematologic_malignancies.

Acquaintance: Elizabeth Zimmermann

Mayo Clinic

View upper information on Velcade.